PolyPid (PYPD) Research & Development (2019 - 2026)
PolyPid (PYPD) posted Research & Development of $5.8 million for Q1 2026, down 7.43% sequentially from $6.2 million in Q4 2025, and down 5.9% YoY from $6.1 million in Q1 2025.
PolyPid (PYPD) Research & Development (2019 - 2026) Analysis & Trends
PolyPid has reported Research & Development for 8 years, with the latest figure at $5.8 million in Q1 2026.
- Quarterly Research & Development fell 5.9% year-over-year to $5.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $23.4 million (down 1.81% YoY) and the FY2025 annual result came in at $23.8 million, up 4.37% from the prior year.
- Research & Development fell to $5.8 million in Q1 2026 per PYPD's latest filing, from $6.2 million in the prior quarter.
- Over five years, Research & Development peaked at $8.7 million in Q1 2022 and troughed at $3.8 million in Q1 2023.
- A 5-year average of $5.7 million and a median of $5.8 million in 2026 frame the typical range for Research & Development.
- The sharpest annual moves came in 2023 and 2024: Research & Development slumped 56.38% in 2023, then surged 56.96% in 2024.
- Over 5 years, Research & Development stood at $4.7 million in 2022, then declined by 1.44% to $4.6 million in 2023, then surged by 53.16% to $7.0 million in 2024, then retreated by 11.51% to $6.2 million in 2025, then declined by 7.43% to $5.8 million in 2026.
- According to Business Quant data, Research & Development over the past three periods registered $5.8 million, $6.2 million, and $5.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 413.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 210.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 97.90 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -588.31 Mn |
| 10 | PolyPid | 113.30 Mn | 106.53 Mn | - | 6.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.13 Mn |
| Mar 31, 2026 | 5.76 Mn |
| Dec 31, 2025 | 6.22 Mn |
| Sep 30, 2025 | 5.26 Mn |
| Jun 30, 2025 | 6.22 Mn |
| Mar 31, 2025 | 6.12 Mn |
| Dec 31, 2024 | 7.03 Mn |
| Sep 30, 2024 | 5.97 Mn |
| Jun 30, 2024 | 4.76 Mn |
| Mar 31, 2024 | 5.05 Mn |
| Dec 31, 2023 | 4.59 Mn |
| Sep 30, 2023 | 3.81 Mn |
| Jun 30, 2023 | 3.96 Mn |
| Mar 31, 2023 | 3.79 Mn |
| Dec 31, 2022 | 4.66 Mn |
| Sep 30, 2022 | 6.24 Mn |
| Jun 30, 2022 | 8.40 Mn |
| Mar 31, 2022 | 8.70 Mn |
| Dec 31, 2021 | 9.62 Mn |
| Sep 30, 2021 | 7.48 Mn |